CRU 5002 | Universitätsmedizin Göttingen

Pancreatic ductal adenocarcinoma (PDAC) remains a major challenge in cancer medicine. The aggressive tumor biology and remarkable resistance to conventional anti-tumor treatments are reflected in a 5-year PDAC survival rate of not more than 10%. Despite significant scientific and clinical efforts the dismal prognosis of PDAC has remained unchanged for almost 30 years, and PDAC has been predicted to become the second leading cause of cancer related death within this decade.

Our Clinical Research Unit 5002 (CRU 5002) explores the mechanistic underpinnings of genome dynamics in PDAC progression and exploits genome dynamics with regard to their therapeutic implications, either as direct targets or as vulnerabilities installed by genome dynamic alteration. We believe that our findings can provide unique and novel avenues to refine PDAC treatment strategies, thus improving the outcome of PDAC patients.

About the CRU 5002

Projects and contact information

Our Concept

The CRU 5002 aims at improving our understanding of genome dynamics in PDAC biology and therapy response and at creating solid foundations for improved PDAC treatment.

Our concept

Scientific and Central Projects

Our projects aim at defining the mechanisms, functional relevance and therapeutic potential of altered genome dynamics and provide central platforms for translational PDAC models, bioinformatic support and data management.

Our projects

Our Team

All of the CRU 5002's staff at a glance. If you require any further information regarding the CRU 5002, please do not hesitate to contact us.

Our team

Events

The 5th German Pancreatic Cancer Research Meeting will be taking place from November 17 to 19, 2025, at the German National Academy of Sciences in Halle (Saale).

Registration and abstract submission are now open on the conference website (www.umh.de/PDAC2025), where you can also find detailed information about the program, which will be updated accordingly.